As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

Enhertu has shown 'unprecedented' trial results, giving hope to mums like Maggie Ngatai.

WILMINGTON, Del.--(BUSINESS WIRE)--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial ...

Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu ...